未知生产厂商
REN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.
REN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.
REN-850 acts by inhibiting leukocyte trafficking and modulating the cell migration driven by multiple chemokine receptors. The oral administration of REN-850 significantly reduces severity of outcomes in multiple in vivo models of multiple Sclerosis (MS) and rheumatoid arthritis (RA).
Investigated for use/treatment in multiple sclerosis.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
